AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist
by Zacks Equity Research
Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.
Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results
by Zacks Equity Research
Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.
Zacks.com featured highlights include: Accenture plc, Builders FirstSource, Inc. and AMN Healthcare Services, Inc.
by Zacks Equity Research
Accenture plc, Builders FirstSource, Inc. and AMN Healthcare Services, Inc. are included in this blog.
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
by Zacks Equity Research
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
Here's Why You Should Retain Thermo Fisher (TMO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.
Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.
Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.
Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth
by Zacks Equity Research
Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.
Here's Why AMN Healthcare (AMN) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
AMN Healthcare (AMN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
3 Stocks With Momentum Anomaly to Create a Winning Portfolio
by Zacks Equity Research
Accenture (ACN), Builders FirstSource (BLDR) and AMN Healthcare Services (AMN) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) given huge market potential in its Invisalign brand and strategic partnerships.
Medtronic (MDT) Gets MHLW Approval for Micra AV Sale in Japan
by Zacks Equity Research
The Micra AV approval is likely to boost Medtronic's (MDT) Cardiac Rhythm Management business while delivering the benefits of leadless pacing in Japan.
Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View
by Zacks Equity Research
Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $107.50, moving +0.41% from the previous trading session.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.
IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment. However, stiff competition is a woe.
Medtronic (MDT) to Buy Affera, Expand in Electrophysiology
by Zacks Equity Research
Affera's full suite of solutions and technologies will complement Medtronic's (MDT) existing atrial and ventricular arrhythmia disease management portfolio.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving the adoption of the da Vince Surgical System. Higher production costs are a woe.
PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability
by Zacks Equity Research
PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.
BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost
by Zacks Equity Research
Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.